



HAL
open science

Development of On-Line Solid-Phase Extraction-Liquid Chromatography Coupled with Tandem Mass Spectrometry Method to Quantify Pharmaceutical, Glucuronide Conjugates and Metabolites in Water

Lea Bazus, Nicolas Cimetiere, Dominique Wolbert, Guy Randon

► **To cite this version:**

Lea Bazus, Nicolas Cimetiere, Dominique Wolbert, Guy Randon. Development of On-Line Solid-Phase Extraction-Liquid Chromatography Coupled with Tandem Mass Spectrometry Method to Quantify Pharmaceutical, Glucuronide Conjugates and Metabolites in Water. *Journal of Chromatography & Separation Techniques*, 2016, 7 (5), pp.1000337. 10.4172/2157-7064.1000337 . hal-01438201

HAL Id: hal-01438201

<https://univ-rennes.hal.science/hal-01438201>

Submitted on 17 Jan 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Development of on-line solid-phase extraction-liquid chromatography**
2 **coupled with tandem mass spectrometry method to quantify pharmaceutical,**
3 **glucuronide conjugates, and metabolites in water.**

4

5 Léa Bazus^a, Nicolas Cimetière*^a, Dominique Wolbert^a and Guy Randon^b

6 ^a Ecole National de Chimie de Rennes, CNRS, UMR 6226, 11 Allée de Beaulieu, CS 50837,

7 35708 Rennes Cedex 7, France

8 ^c Veolia Eau, Direction Technique Région Ouest, 8 allée Rodolphe Bopierre, 35020 Rennes

9 Cedex 9, France

10

11 *Corresponding author phone : +33 2 23 23 80 14

12 e-mail address : Nicolas.cimetiere@ensc-rennes.fr

13

14 **Abstract:**

15 The present work describes the development of an analytical method, based on automated
16 on-line solid phase extraction followed by ultra-high-performance liquid chromatography
17 coupled with tandem mass spectrometry (SPE-LC-MS/MS) for the quantification of 37
18 pharmaceutical residues, covering various therapeutic classes, and some of their main
19 metabolites, in surface and drinking water. A special attention was given to some
20 glucuronide conjugates and metabolites of active substances. Multiple Reaction Monitoring
21 (MRM) was chosen and two transitions per compound are monitored (quantification and
22 confirmation transitions). Quantification is performed by standard addition approach to
23 correct matrix effect. The method provides limit of quantification inferior to 20 ng.L^{-1} for all
24 compounds. The methodology was successfully applied to the analysis of surface water and
25 drinking water of 8 drinking water treatment plant in west of France. The highest drug
26 concentrations in surface water and drinking water were reported for ketoprofen,
27 hydroxyibuprofen, acetaminophen, caffeine and danofloxacin.

28

29 **Key words:** *pharmaceuticals, automated on-line solid phase extraction, liquid*
30 *chromatography, tandem mass spectrometry, water analysis*

31 **1. Introduction**

32 Pharmaceuticals are an important group of emerging contaminants in the environment [1].

33 In recent years many reports have been made on the occurrence of the large, differentiated
34 group of pharmaceuticals in wastewater, surface water, ground water and drinking water in
35 many countries [2-9]. After administration, most pharmaceuticals are not completely
36 metabolized. The unmetabolized parent pharmaceutical and some metabolites are
37 subsequently excreted from the body via urine and faeces [10]. Reports have shown that
38 many pharmaceuticals do not totally degrade during conventional wastewater treatment
39 [11,12]. The concentrations of individual compounds in wastewater, surface water, ground
40 water and drinking water are typically in the range of ng/L to µg/L. The effect on long-term
41 pharmaceutical residues in aquatic environments remains largely unknown. In addition, the
42 risks to the environment are evaluated for a particular drug, while we find a mixture of all
43 these compounds in aquatic environments. Studies have shown that combinations of drugs
44 may be more powerful than the simple addition of two drugs individually toxic effects [13-
45 14].

46 Wastewater effluent is a major source for the input of pharmaceuticals to the environment
47 [11;12], which can then migrate through water systems and into source water intended for
48 drinking water supplies. Advanced wastewater treatment processes have been shown to
49 significantly reduce the concentrations of emerging contaminants. However, some
50 compounds are not completely removed even if treatment techniques are used [15].
51 Moreover, most of the WWTP do not include these specifically designed treatment units.

52 In this context, sensitive analytical methods allowing the quantification of many pollutants at
53 trace concentration is essential. Solid Phase Extraction (SPE) is the most commonly used
54 technique to prepare sample before analysis. SPE allows the concomitance of analyte

55 concentration and interferences removal [16;17]. To date, most of the published multi-
56 residue methods for the determination of ultra traces of pharmaceuticals compounds in
57 surface and drinking water use off-line SPE followed by gas chromatography mass
58 spectrometry (GC-MS) or by liquid chromatography-tandem mass spectrometry (LC-
59 MS/MS) [2-5;7;9;12]. However, On-line Solid Phase Extraction is an emerging method for
60 analysis of the trace compounds of organic micropollutants (reactive drugs, pesticides...).
61 This technique has many advantages: saving time, automated method, reproducibility, very
62 low solvent consumption, small sample handling, SPE cartridges reuse... [17]. The cartridges
63 used to concentrate pharmaceuticals residues are usually OasisTM HLB or hydrophobic resins.
64 [18;19]. This technique is generally coupled to liquid chromatography with UV, MS or MS/MS
65 detector with reversed phase column [20-24].

66 The objectives of this work has been to develop a fully automated method to analyze a
67 number of target compounds belonging to different therapeutical classes and some by
68 product using on-line SPE directly coupled to liquid chromatography tandem mass
69 spectrometry (LC-MS/MS). This analytical technique limits matrix effect impact. However
70 remaining, interfering species can affect the analytical train, especially natural organic
71 matter may coeluate with targeted compounds which leads to a signal disturbance causing
72 over/underestimation or false positive results, or some compounds may react with targeted
73 molecules during sampling and storage [25].

74 This method was evaluated in different water matrices: UltraPure Water (UPW) to develop
75 the analytical method, surface water and drinking water for validation.

76

77 **2. Material and methods**

78

79 *2.1. Compound selection*

80

81 32 pharmaceuticals and 3 metabolites and 2 glucuronide conjugates were selected for this
82 study (Table 1 and Table S1). These molecules were chosen based on the following criteria: i)
83 selected compounds should exhibit a variety of physical properties, such as functional
84 groups and polarity, ii) they should represent of a diversity of pharmaceutical classes, iii)
85 high frequencies of environmental occurrence, iv) low removal efficiencies by drinking water
86 and wastewater treatment techniques in France or others countries [2-9]. Table 1 lists the 37
87 molecules selected for our study and their optimized parameters for quantification, chemical
88 structure is provided in the figure S1 in Supporting Information. Thereafter, the molecules
89 will be called by the short identifiers which are given in the table 1. The pharmaceutical
90 classes represented are cardiovascular drugs, anticancer agents, human or veterinary
91 antibiotics, neuroleptics, non-steroidal anti-inflammatory drugs and hormones.

92

93 *2.2. Pharmaceutical standards and reagents*

94 All pharmaceutical compounds have minimum 90% purity, used as received in solid form and
95 were obtained from Sigma Aldrich (FRANCE). Ultra pure water (UPW) was delivered by a
96 ElgaPureLab System (resistivity 18.2 M Ω .cm, COT < 50 μ g C/L). Chromatographic and SPE
97 solvents, acetonitrile (ACN) with or without 0.1 % formic acid (FA) and methanol (MeOH)
98 were purchased from JT Baker (LC-MS grade) and were used in association with UPW in also
99 or not with 0.1 % formic acid.

100 All concentrated stock solution of individual pharmaceuticals were prepared in methanol
101 with a concentration of 500 mg.L⁻¹ and stored at -20 °C. The mixed spiking solutions were
102 prepared in methanol at 500 μ g.L⁻¹ and stored at 4°C during 15 days maximum. This mixed
103 spiking solution is daily diluted in water to obtained 500 ng.L⁻¹ before use for standard

104 addition. Concentrations prepared for analytical development and to quantify the target
105 compounds in the different matrices are: 5, 10, 20, 50, 100, 250 and 500 ng.L⁻¹.

106

107 *2.3. On-line solid phase extraction and liquid chromatography*

108 The analytical system consists of an automated SPE sampler coupled with an LC-MS/MS. The
109 online extraction was carried out using a 2777 autosampler equipped with two parallel
110 OasisTM HLB cartridge (Direct Connect HP 20µm, 2.1x30mm) working sequentially. The
111 switching from the loading flow pattern, to elution, then conditioning and back to loading is
112 performed using two six positions EverflowTM valves. Loading eluent (UPW) and conditioning
113 eluent (methanol) were provided by a quaternary pump (AcquityTM QSM). Elution of the
114 analytes from the SPE cartridge to LC system was achieved by connected the cartridge to the
115 inlet of the separation column and using the initial chromatographic elution solution.

116 Separation was carried out using a reversed phase column (AcquityTM BEH C18, 100 mm x 2.1
117 mm ID, 17µm) placed in an oven (45°C). The elution gradient was produced by a binary
118 pump (AcquityTM BSM) and was optimized and will be described later in the manuscript.

119

120 *2.4. Mass spectrometry*

121 The mass spectrometer (Quattro Premier, MicromassTM) operates with the following
122 conditions: cone gas (N₂, 50 L.h⁻¹, 120 °C), desolvation gas (N₂, 750 L.h⁻¹, 350 °C), collision
123 gas (Ar, 0.1 mL.min⁻¹), capillary voltage (3000V). The ionization source of the mass
124 spectrometer is an electrospray (ESI) used either in the positive or the negative mode
125 according to pharmaceutical compounds structure (table 1). All the analysis, are made in
126 "multiple reaction monitoring" (MRM) mode, the parent ion from the ESI source is selected
127 in the first quadrupole (pseudomolecular ion in most cases) and fragmented in the collision

128 cell. One or more fragments (quantification ion and, when available, confirmation ions) are
129 then selected by the third quadrupole before being detected by a photomultiplier. This
130 mode allows high sensitivity and selectivity.

Table 1: List of the 35 pharmaceuticals with pharmaceutical class Molecule (short identifier), N°CAS, MW (g/mol), formula, mass parameter and retention time

Pharmaceutical class	Molecule (short identifier)	N°CAS	MW (g/mol)	formula of the active substance	ESI	Parents ion	Daughter ion(Q)	Cones (V)	Collisions (V)	Confirmation ion	Collisions (V)	Dwell time (ms)	Tr (min)
Cardiovascular drugs	Amlodipin (AML)	111470-99-6	567.05	C ₂₀ H ₂₅ ClN ₂ O ₅	+	409.6	238.1	18	11	409.6	13	50	4.03
	Atenolol (ATE)	29122-68-7	266.34	C ₁₄ H ₂₂ N ₂ O ₃	+	267	145	34	26	74	23	50	1.18
	Losartan (LOS)	124750-99-8	461	C ₂₂ H ₂₃ ClN ₆ O	+	423.6	405.2	30	12	207	22	50	4.25
	Naftidrofuryl (NAF)	03200-6-4	473.56	C ₂₄ H ₃₃ NO ₃	+	384.6	99.7	40	21	84.7	25	50	4.29
	Pravastatin (PRA)	81131-70-6	446.51	C ₂₃ H ₃₆ O ₇	-	423.2	100.6	34	23	321.1	16	50	2.63
	Propranolol (PRO)	525-66-6	259.4	C ₁₆ H ₂₁ NO ₂	+	260.2	116	34	18	183	18	50	3.33
	Gemfibrozil (GEM)	25812-30-0	250.33	C ₁₅ H ₂₂ O ₃	-	249	121	34	23			50	4.95
Trimetazidin (TRI)	13171-25-0	339.26	C ₁₄ H ₂₄ Cl ₂ N ₂ O ₃	+	267.4	180.9	21	16	165.8	26	50	1.18	
anticancer agent	Tamoxifen (TAM)	10540-29-1	371.5	C ₂₆ H ₂₉ NO	+	372.5	72	45	14			50	5.42
	Hydroxytamoxifen (OH-TAM)	68047-06-3	387.2	C ₂₆ H ₂₉ NO ₂	+	388.2	72	45	14			50	4.58
	Ifosfamide (IFO)	3778-73-2	261	C ₇ H ₁₅ Cl ₂ N ₂ O ₂ P	+	261.02	153.95	25	22	92.04	25	75	3
Human Antibiotic	Doxycycline (DOX)	24390-14-5	512.94	C ₂₂ H ₂₄ N ₂ O ₈	+	445.5	428.2	30	18	153.8	28	50	2.95
	Erythromycin (ERY)	114-07-8	769.96	C ₃₇ H ₆₇ NO ₁₃	+	734.2	158	28	30	576.2	19	50	3.68
	Ofloxacin (OFX)	82419-36-1	361.37	C ₁₈ H ₂₀ FN ₃ O ₄	+	362	318	34	19	261	28	80	1.35
	Sulfaméthoxazole (SUL)	723-46-6	253.278	C ₁₀ H ₁₁ N ₃ O ₃ S	+	254	92	26	28	156	16	50	2.74
	Trimetoprim (TRP)	738-70-5	290.3	C ₁₄ H ₁₈ N ₄ O ₃	+	291.2	230	24	24	261.1	26	50	1.18
Veterinarian Antibiotic	Danofloxacin (DANO)	112398-08-0	357.38	C ₁₉ H ₂₀ FN ₃ O ₃	+	358.5	314	35	19	283	25	50	1.53
	Lincomycin (LINCO)	859-18-7	461.37	C ₁₈ H ₃₄ N ₂ O ₆ S	+	407.6	125.9	40	28	359.3	18	50	1.23
	Sulfadimerazine (SFZ)	57-68-1	278.33	C ₁₁ H ₁₂ N ₄ O ₂ S	+	279.4	185.9	29	16	91.7	26	50	1.91
	Tylosin (TYL)	74610-55-2	1066.19	C ₄₆ H ₇₇ NO ₁₇	+	917	174	60	37	773	29	50	3.84
Neuroleptic	Carbamazepine (CBZ)	298-46-4	236.27	C ₁₅ H ₁₂ N ₂ O	+	237.1	194	28	19	179	39	50	3.85
	Epoxy-carbamazepine (Ep-CBZ)	36507-30-9	252.27	C ₁₅ H ₁₂ N ₂ O ₂	+	253.3	179.9	28	28	236	12	50	3.2
	Oxazepam (OZP)	604-75-1	286.71	C ₁₅ H ₁₁ ClN ₂ O ₂	+	287.4	241	34	20	269.1	14	50	4.08
	Oxazepam (Glu-OZP)	6801-81-6	462.84	C ₂₁ H ₁₉ ClN ₂ O ₈	+	463.2	287.1	26	15	269	26	15	3.34
Non-steroidal anti-inflammatory drugs (NSAID)	Diclofenac (DICLO)	15307-79-6	294.14	C ₁₄ H ₁₁ Cl ₂ NO ₂	+	296.1	250	22	10	214.1	25	100	5.5
	Ibuprofen (IBU)	15687-27-1	206.28	C ₁₃ H ₁₈ O ₂	-	205	161	17	7			50	4.06
	Hydroxyibuprofen (OH-IBU)	51146-55-5	222.28	C ₁₃ H ₁₈ O ₃	-	221.2	177	19	9	158.7	13	50	1.2
	Ketoprofen (KETO)	22071-15-4	254.28	C ₁₆ H ₁₄ O ₃	+	255	209	29	12	105	22	100	4.14
	Salicylic acid (SCA)	69-72-7	138.12	C ₇ H ₆ O ₃	-	137	92.6	30	14	64.7	28	70	1.16
Miscellaneous	Acetaminophen (PARA)	103-90-2	151.16	C ₈ H ₉ NO ₂	+	152	110	25	15	90	10	50	1.24
	Acetaminophen Glucuronide (Glu-PARA)	16110-10-4	327.29	C ₁₄ H ₁₇ NO ₈	+	350	173.8	33	15				1.64
	Caffeine (CAF)	58-08-2	194.19	C ₈ H ₁₀ N ₄ O ₂	+	195.1	137.7	37	18	109.7	22	50	1.35
	Hydrochlorothiazide (HCTZ)	58-93-5	297.74	C ₇ H ₈ ClN ₃ O ₄ S ₂	-	296.2	77.6	42	28	204.8	22	50	1.5
Hormone	Ethinylestradiol (EE)	57-63-6	296.4	C ₂₀ H ₂₄ O ₂	-	295.2	144.9	54	40	183	35	50	4.07
	17β-Estradiol (βE)	50-28-2	272.38	C ₁₈ H ₂₄ O ₂	-	271.1	145	50	38	183	41	70	3.89
	Estrone (EO)	53-16-7	270.37	C ₁₈ H ₂₂ O ₂	-	269.1	145	53	35	183	36	70	4.14
	Progesterone (PGT)	57-83-0	314.46	C ₂₁ H ₃₀ O ₂	+	315.2	97	32	24	109	26	50	5.77

132

133 3. Results and discussion

134 3.1. Mass spectrometry optimization

135 The selection of optimum detection parameters (collision energy, cone voltage, ionization
136 mode) for each targeted compound was carried out by introducing a standard diluted single
137 solute solution at 5 mg.L⁻¹ directly in the mass spectrometer (without separation). The
138 pseudo-molecular ion ($[M+H]^+$ or $[M-H]^-$) was selected as the parent ion. Acetaminophen-
139 glucuronide was ionized as sodium adducts ($[M+Na]^+$) and the daughter ion correspond to
140 the sodium adduct of paracetamol obtained by the loss of glucuronic acid. Similar
141 fragmentation pattern with loss of carbohydrate group was observed with Glu-OZP ($[M+H]^+$
142 $\rightarrow [M-Glu+H]^+$). In some cases, the standard molecules were purchased as sodium or
143 chloride salt so molecular weight of the commercial product indicated in the table 1 does
144 not correspond to the formula of active compounds. So the molecular weights indicated in
145 the table 1 do not correspond to the mass of the pseudo molecular ion (AML, LOS, NAF, PRA,
146 TRI, DOX, ERY, LINCO and TYL). Positive mode was selected for most of the molecules and 8
147 analytes were ionized under negative mode because of their tendency to loose a proton.
148 Two transitions are chosen for quantification and confirmation. If possible transition
149 corresponding to the loss of simples fragments (ie. $-H_2O$ or $-CO_2$) has been preferred for
150 quantification or confirmation transition. Only one transition could be found to 4 molecules:
151 Ibuprofen, Gemfibrozil, Tamoxifen and Hydroxy-Tamoxifen. The results are presented in
152 table 1.

153 3.2. On-line SPE method development

154 The efficiency of the SPE step was studied using two different types of SPE cartridge phases :
155 Oasis HLB (Direct Connect HP 20 μ m, 2.1x30mm) and XBridge C18 (Direct Connect HP 10 μ m,
156 2.1x30mm). The low energie interactions are predominant with the C18 phases, unlike for
157 HLB phases where the dipole-dipole interactions are brought into play. Table 2 presents
158 characteristics (log(Kow), pka, coefficient of dissociation, dipolar moment) of molecules. The
159 extraction yield was then calculated according to the following equation:

$$Extraction\ yield\ (\%) = 100 * \frac{Area_{SPE\ mode}}{Area_{conventional\ mode}}$$

160 For each compounds, the area obtained with the injection of 5mL of solution at 100 ng.L⁻¹ in
161 SPE mode was compared to the area obtain in conventional mode (Vinj=5 μ L; C=100 μ g.L⁻¹).

162 The results are presented in figure 1. In a global overview the extraction yields are better
163 with the Oasis HLB phase in comparison to the C18 phase. 11 molecules have slightly better
164 extraction yields with the XBridge C18 media. Given these results, Oasis HLB phase was
165 chosen for the SPE cartridges. The extraction yields are between 24% and 96%. Six
166 molecules, among them three hormones (ATE, TRI, DOX, EE, β E and EO) have extraction
167 yields inferior or equal to 50% but the signal is sufficient for our analysis given the
168 reproducibility of the extraction step. The loading time and flow rate influence the analyte
169 retention onto the preconcentration cartridge. If the loading time is too short, a part of the
170 molecules of interest will not be collected in the cartridge. MeOH is used for the cartridge
171 conditioning during 3 minutes and UPW for the loading sample during 5.5 minutes at
172 2mL/min. 5mL of sample are injected onto the cartridge. Elution of our compounds is made
173 using the initial chromatographic conditions. The preconcentration method takes 8.5
174 minutes. The pH of samples and eluents was also optimized to try to improve the extraction
175 yields. The figure 2 shows the effect of pH (3, 7 and 9) on molecule's recovery yields. Most of

176 the targeted compounds were efficiently extracted at neutral pH values. The recovery yields
 177 of thirteen molecules (LOS, GEM, TAM, OH-TAM, IFO, TYL, DICLO, PARA, CAF, CBZ, OZP, PGT
 178 and ERY) do not show significant pH dependence. ATE, NAF and LINCO were comparatively
 179 more recovered under neutral condition due to the amine/ammonium repartition for the
 180 low pH values. DANO and OFX are amphoteric molecules and exhibit higher recovery yields
 181 under acid extraction than under neutral conditions. AML and OFX have extraction yields
 182 superior to 100%, the differences may be included within the experimental errors. Three
 183 hormones have a better extraction yields at basic pH while below 23% for an acid pH. The
 184 SPE appears globally controlled by the carboxylic functions. The best compromise to our
 185 analytical method is the neutral pH.


186

Tableau 2: log(Kow), pka, coefficient of dissociation and dipolar moment of molecules

Molecule	Log(Kow)	pka	coefficient of dissociation	dipolar moment
AML	3	8.6	$5.00 \cdot 10^{-5}$	
ATE	0.16	9.6	$1.50 \cdot 10^{-5}$	5.71
LOS	1.19	5,5	$8.80 \cdot 10^{-3}$	
NAF	4.56	8.7	$4.70 \cdot 10^{-5}$	2.83
PRA	1.35	4.5	$5.60 \cdot 10^{-3}$	
PRO	3.48	9.5	$1.70 \cdot 10^{-5}$	
GEM	4.77	4.7	$4.40 \cdot 10^{-3}$	
TRI	1.04	4.3/8.9	$7.00 \cdot 10^{-3}$	
TAM	3.24	8.76	$4.20 \cdot 10^{-5}$	
OH-TAM	4.74	3.2/6.4	$6.30 \cdot 10^{-4}$	
IFO	0.86	13.2	$2.50 \cdot 10^{-7}$	
DOX	2,37	3.5/7.7	$1.40 \cdot 10^{-4}$	
ERY	3,02	8.8	$3.90 \cdot 10^{-5}$	
OFX	0.65	6.1	$9.40 \cdot 10^{-4}$	7.2
SUL	0.79	5.7	$1.40 \cdot 10^{-3}$	
TRP	0.91	7.1	$2.80 \cdot 10^{-4}$	
DANO	0,44	6.0	$9.90 \cdot 10^{-4}$	
LINCO	0,56	7.6	$1.60 \cdot 10^{-4}$	
SFZ	0.19	7	$3.20 \cdot 10^{-4}$	7.34
TYL	1.63	7.7	$1.40 \cdot 10^{-4}$	
CBZ	2,77	7	$1.00 \cdot 10^{-7}$	3.66

Ep-CBZ	1.58	15.9	$1.00 \cdot 10^{-8}$	
OZP	2,24	1.7/11.6	$1.30 \cdot 10^{-1}$	
DICLO	4,51	4	$8.00 \cdot 10^{-3}$	4.55
IBU	3,79	4.5	$5.30 \cdot 10^{-3}$	4.95
OH-IBU	3,97	4.8	$3.90 \cdot 10^{-3}$	
KETO	3.12	4.45	$6.00 \cdot 10^{-3}$	
SCA	1,19	3	$3.10 \cdot 10^{-2}$	
PARA	0,49	9.5	$1.80 \cdot 10^{-5}$	4.55
CAF	-0.091	14	$2.10 \cdot 10^{-1}$	3.71
HCTZ	-0,07	7.9	$1.00 \cdot 10^{-4}$	
EE	3,67	10.3	$7.00 \cdot 10^{-6}$	
βE	3.57	10.71	$4.40 \cdot 10^{-6}$	1.56
EO	3.69	10.4	$6.00 \cdot 10^{-6}$	3.45
PGT	4	18.9	$3.50 \cdot 10^{-10}$	

187




188

189 **Figure 1: Extraction yields calculated for the two cartridges (Oasis HLB and Xbridge C18) tested for all**

190

molecules in neutral pH

191



192

193

Figure 2: Extraction yields calculated for the 3 pH (3, 7 and 9) for all analytes

194

3.3. Chromatographic conditions

195

Three chromatographic columns packed with different stationary phases were studied, two

196

using the reversed phase mode: Acquity BEH C18 (100 mm x 2.1 mm ID, 1.7 μ m) and Acquity

197

HSST3 (100 mm x 2.1 mm ID, 1.7 μ m). These two columns have the same stationary phase

198

but Acquity HSST3 should allow for better separation of polar molecules due to the greater

199

proportion of residual silanol groups. The third column has a polar stationary phase: BEH

200

amide (100 mm x 2.1 mm ID, 1.7 μ m) in order to separate the analyte using hydrophilic

201

interaction liquid chromatography (HILIC). Comparing the chromatograms obtained for the

202

C18 and HSST3 column, the results are quite similar. Seven minutes are required to obtain

203

sufficient separation. It should be underlined that the resolution between two consecutive

204

peaks was quite low. However, because the quantification was done using different MRM

205

channels this poor resolution does not affect the analytical performances.

206

Figure 3 summarizes the results by plotting the polarity (log Kow) as function of the capacity


207

factor of the molecule, molecules with $k' < 1$ form the unretained groups with no log(kow)

208

dependences. For the others, correlation between k' and log(kow) shows two adverse

209 behaviours in relation with the different stationary phase, BEH and HSST3 on the one part
 210 and HILIC on the second part. Reversed phase HPLC columns (BEH C18 and HSST3) provide a
 211 satisfactory separation with k' ranging from 0.93 to 9.91 according to the polarity of the
 212 considered compounds. However numerous analytes exhibit a high polarity and were poorly
 213 retained using reversed-phase HPLC. Normal phase HPLC column (BEH Amide) provides
 214 separation with k' ranging from 0.1 to 9.6. Molecules retained by the reversed phase HPLC
 215 column are not retained in normal phase HPLC with $k' < 1$. Moreover, peak tailing are
 216 observed for some molecules with HSST3 (SUL, GEM, DOX) and with HILIC column (PARA,
 217 DANO, HCTZ, TRI). The best compromise for our analyses is to use the BEH C18 column.



218

219

220 **Figure 3: Polarity (log Kow) as function of the capacity factor for all molecules and for 3 chromatographic**
 221 **columns**


222

223 The mobile phase flow rate was $0.4 \text{ mL} \cdot \text{min}^{-1}$, corresponding to the optimum zone of the Van
 224 Deemter curve with this column [26]. The elution conditions were optimized. Two
 225 chromatographic separation methods were needed to quantify all the target analytes.


226 Indeed, analytes with ESI+ detection have better sensitivity with acidified eluents (with 0.1%
 227 of formic acid) unlike molecules with ESI- detection which have better sensitivity with
 228 neutral eluents. Moreover, the combination of both positive and negative ionization mode
 229 during the same run does lead to a decrease of the sensibility.

230 The elution conditions start with 20% ACN/80% UPW during 1 minute followed by a gradient
 231 90% ACN within 6 minutes and remain constant for 1 min before returning to initial
 232 conditions, details of the method are presented in Supporting information (Section B –
 233 Figures S1-S3)

234 Examples of chromatograms obtained with a solution of 50 ng.L⁻¹ in UPW and the eluent
 235 program are presented in Figure 4. 12 molecules elute within two minutes for the ESI+/acid
 236 eluent method. As mentioned above, the detection mode (MRM) allows an accurate
 237 quantification even if the resolution is low.



238



239

240 **Figure 4: Chromatogram obtained at 50ng/L in UPW. a. first method with ESI+. b. Second method with ESI-**

241

242 **3.4. Quantification limit and matrix effect**

243 Standard addition method was selected for calibration method in order to minimize or

244 eliminated matrix effects. Figures 5 present examples of calibration curve for CBZ in UPW,

245 Groundwater (GW), Drinking water (DW) and Surface water (SW). Limit of quantification

246 (LOQ) were determined for all targeted compounds in UPW and GW with the equation given

247 in figure 5a, in accordance with the AFNOR NF-T-90-210 norm for all analytes. GW could be

248 considered free of pharmaceuticals residues because GW is drawn from a well recovering

249 the waters on a small watershed without collective or on-site sanitation water release, and

250 UPW can be considered as a matrix blank. Negatively ionized molecules (EO, BE, EE, HCTZ,

251 SCA, IBU, OH-IBU, GEM, PRA) have higher limits of quantification because the background

252 noise is more important than for ESI⁺. The values of the quantification limit of targeted

253 compounds are presented in figure 6a. LOQ values obtained range from 5 to 17ng/L. These


254 limits of quantification are sufficient for our purpose.

255 Measurement errors were incorporated by defining the 90% confidence intervals (figure 5b).
256 Figures 5c and d show standard addition calibration lines of CBZ in GW and DW.
257 Comparisons of the slopes obtained with real waters to the slope obtain in the blank
258 (a_{GW}/a_{UPW} and a_{DW}/a_{UPW}) allow a comprehensive approach of the matrix effects. These slope
259 ratios are presented in figure 6b for all analytes. The matrix effect is a classical phenomenon
260 which can be very important in liquid chromatography coupled with mass spectrometry
261 because of the ionization process may be drastically influenced by the presence of
262 interfering species. Many studies have already described this phenomenon especially with
263 wastewaters. The presence of organic or inorganic substance can cause inhibition (<1) or
264 enhancement (>1) of a compound's signal [27-29]. In our case, natural organic matter may
265 disturb the SPE step or mass ionization so the rationalization of the slopes provides a global
266 overview of matrix effect but do not allow to identify the critical step.

267 In figure 6b, matrix effects are not significant when the ratio is close to 1. In drinking water
268 this ratio was close to 1 for most of the analytes, only AML has a ratio superior to 5.

269

270



271

272 Figure 5: a. equation of LOQ determination. b. Example of standard addition for CBZ with 90% confidence interval. c.
 273 and d. Example of standard addition in GW and DW for CBZ

274




Figure 6: a. LOQ in UPW and GW for all molecules b. Matrix effects of all analytes

275

276

277

278 3.6. Analysis of surface water and drinking water

279 The developed method was used to determine the concentration of 37 pharmaceuticals

280 substances in inflow and outflow waters of 8 drinking water treatment plants (DWTP) in


281 west of France. The samples were collected once a month between October 2013 and April

282 2015, resulting in an average of 100 inflow and 100 outflow concentration values for each

283 molecule. Nine pharmaceuticals have not been detected or with concentrations below the

284 LOQ (AML, TAM, OH-TAM, IFO, ERY, LINCO, EE, β E and PGT). Figure 7 shows the


285 concentrations of 27 pharmaceuticals or metabolites in surface water as a box plot; this
286 statistical representation summarizes the data, for each compound, by the mean values,
287 median value, first and third quartiles and observed extrema. 7 molecules (PARA-GLU, KETO,
288 OH-IBU, DANO, PARA, SCA, CAF) have a mean concentration greater than 50 ng.L⁻¹. 10
289 molecules were quantified with mean concentrations higher than 10 ng.L⁻¹ (GEM, CBZ,
290 DICLO, OZP, OFX, IBU, HCTZ, ATE, PRO and DOX). The last detected 10 molecules exhibit
291 mean concentration lower than 10 ng.L⁻¹ (SFZ, SUL, TRI, PRA, Ep-CBZ, TRP, EO, NAF, TYL,
292 LOS). For some molecules, large differences between the extrema are observed (PARA-Glu,
293 KETO, OH-IBU, SCA). These differences depend on the sampling date essentially. It should be
294 underlined that median values are close to mean values indicating that extrema values do
295 not play an important role. The maximum observed concentration in surface water was 650
296 ng.L⁻¹ for KETO. Detection frequencies depend on compounds and range from 100%
297 occurrence for CAF and PARA and 9% for TYL. 13 molecules (PARA-Glu, KETO, OH-IBU,
298 DANO, PARA, CAF, SCA, DICLO, GEM, CBZ, OZP, OFX and ATE) were quantified in more than
299 50% of surface water samples. In drinking water (figure 8), six molecules (KETO, PARA-Glu,
300 OH-IBU, DANO, PARA and CAF) were quantified in 90% or more of the drinking water
301 samples. These 6 molecules were also the most quantified molecules in surface water. The
302 overall mean concentration values are between 4 (OZP) and 327 ng/L. The maximum
303 concentration found was 650 ng/L for KETO. For drinking water, the same remark than for
304 surface water may be made concerning the gap between minimum and maximum
305 concentrations: the eight drinking water treatment plants operate different treatment
306 chains with different type of water resources.



307
308

309 **Figure 7: overall mean concentrations (♦), median value, first and third quartiles and extrema of 27**
310 **molecules detected on average above LOQ in surface waters and detection frequencies (% , broken line).**

311



312

313 **Figure 8: overall mean concentrations(♦), median value, first and third quartiles and extrema for 14**
314 **molecules detected in tap waters and detection frequencies (% , broken line).**

315

316 4. Conclusion

317 A multiresidue analysis was developed using on-line solid phase extraction connected to
318 liquid chromatography coupled with tandem mass spectrometry in order to quantify residue
319 trace levels 35 pharmaceuticals compounds in surface and drinking water. The short
320 implementation time needed to achieve the preconcentration and the analysis, 17 minutes
321 for the positive mode method and 15 minutes for the negative mode method is among the
322 most significant advantages of this method compared to off-line solid phase extraction. The
323 developed method with a preconcentration factor of one thousand showed detection limits
324 compatible with the study of environmental matrices with very low analyte concentrations.
325 The limits of detection and quantification are between 1.5 and 4 ng/L and 4 and 17ng /L,
326 respectively. Standard addition was chosen for the quantification of molecules in water
327 samples to overcome the matrix effects and provide an accurate determination of targeted
328 compounds. Among all studied substances, doxycycline appeared to be the most affected by
329 a matrix effect. The developed methods were applied to eight surfaces and drinking water.
330 In surface water, 12 molecules could be quantified in almost all analyzed samples with a
331 maximum concentration value of 650ng/L for Ketoprofen. In drinking water, 5 molecules
332 could be regularly detected, with overall mean concentration values between 20 à 120ng/L.

333 References:

334 [1] Jorgensen, S.E., Halling-Sorensen, B., Drugs in the environment *Chemosphere* 40, 2000,
335 691.

336 [2] Gros, M., Rodriguez-Mozaz, S., Barceló, D. (2012). Fast and comprehensive multi-residue
337 analysis of a broad range of human and veterinary pharmaceuticals and some of their
338 metabolites in surface and treated waters by ultra-high-performance liquid chromatography

339 coupled to quadrupole-linear ion trap tandem mass spectrometry. *Journal of*
340 *Chromatography A*, 1248, 104– 121.

341 [3] Togola, A. and H. Budzinski (2008). Multi-residue analysis of pharmaceutical compounds
342 in aqueous samples. *Journal of Chromatography A* 1177(1), 150-158.

343 [4] Viglio, L., Aboulfald, K., Deneshvar, A., Prevost, M., Sauve, S. (2008). On-line solid phase
344 extraction and liquid chromatography/tandem mass spectrometry to quantify
345 pharmaceuticals, pesticides and some metabolites in wastewaters, drinking, and surface
346 waters. *J. Environ. Monit.*, 10, 482–489.

347 [5] Kim, S.D., Cho, J., Kim, I.S., Vanderford, B.J., Snyder, S.A. (2007). Occurrence and removal
348 of pharmaceuticals and endocrine disruptors in South Korean surface, drinking, and waste
349 waters. *Water Research*, 41, 1013-1021.

350 [6] Miege, C., Choubert, J.M., Ribeiro, L., Eusebe, M., Coquery, M. (2009). Fate of
351 pharmaceuticals and personal care products in wastewater treatment plants – Conception of
352 a database and first results. *Environmental Pollution*, 157, 1721–1726.

353 [7] Moldovan Z. (2006) Occurrences of pharmaceutical and personal care products as
354 micropollutants in rivers from Romania. *Chemosphere* 64,1808-1817

355 [8] Mompelat, S., Le Bot, B., Thomas, O. (2009). Occurrence and fate of pharmaceutical
356 products and by-products, from resource to drinking water. *Environment International*, 5,
357 803-814

358 [9] Stackelberg, P.E., Gibs, J., Furlong, E.T., Mayer, M.T., Zaugg, S.D., Lippincott, R. (2007).
359 Efficiency of conventional drinking-water-treatment processes in removal of
360 pharmaceuticals and other organic compounds. *Science of the Total Environment*, 377, 255-
361 272.

- 362 [10] de Graaff, M.S., Vieno, N.M., Kujawa-Roeleveld, K., Zeeman, G., Temmink, H., Buisman,
363 C.J.N., (2011). Fate of hormones and pharmaceuticals during combined anaerobic treatment
364 and nitrogen removal by partial nitrification-anammox in vacuum collected black water.
365 *Water Research*, 45 (1), 375.
- 366 [11] Daughton, C.G., Ternes, T.A.,(1999), Pharmaceuticals and personal care products in the
367 environment: agents of subtle change? *Environ. Health Perspect.* 107, 907.
- 368 [12] Vieno, N.M., Tuhkanen, T., Kronberg, L. (2006). Analysis of neutral and basic
369 pharmaceuticals in sewage treatment plants and in recipient rivers using solid phase
370 extraction and liquid chromatography–tandem mass spectrometry detection. *Journal of*
371 *Chromatography A*, 1134, 101-111
- 372 [13] Viglio, L., Aboufald, K., Deneshvar, A., Prevost, M., Sauve, S. (2008). On-line solid phase
373 extraction and liquid chromatography/tandem mass spectrometry to quantify
374 pharmaceuticals, pesticides and some metabolites in wastewaters, drinking, and surface
375 waters. *J. Environ. Monit.*, 10, 482–489.
- 376 [14] Carlsson, C., Johansson, A.K., Alvan, G., Bergman, K., Kuhler, T., (2006) Are
377 pharmaceuticals potent environmental pollutants? Part I: Environmental risk assessments of
378 selected active pharmaceutical ingredients. *Science of the Total Environment* 364 (2006) 67 –
379 87.
- 380 [15] Cleuvers, M. (2003) Aquatic ecotoxicity of pharmaceuticals including the assessment of
381 combination effects. *Toxicology Letters* 142, 185-194.

- 382 [16] Gerrity, G., Gamage, S., Holady, S.J., Mawhinney, D.B., Quinones, O., Trenholma, R.A.,
383 Snyder, S.A., (2011). Pilot-scale evaluation of ozone and biological activated carbon for trace
384 organic contaminant mitigation and disinfection, *water research*, 45, 2155-2165
- 385 [17] Rodriguez-Mozaz, S., Lopez de Alda, M.J., Barcelo, D., (2007). Advantages and
386 limitations of on-line solid phase extraction coupled to liquid chromatography-mass
387 spectrometry technologies versus biosensors for monitoring of emerging contaminants in
388 water. *Journal of chromatography A.*, 1152, 97-115.
- 389 [18] Trenholm, R., Vanderford, B., Snyder, S., (2009). On-line solid phase extraction LC-
390 MS/MS analysis of pharmaceutical indicators in water: A green alternative to conventional
391 methods. *Talanta*, 79, 1425-1432.
- 392 [19] Miège, C., Favier, M., Brosse, C., Canler, J.P., Coquery, M., (2006). Occurrence of
393 betablockers in effluents of wastewater treatment plants from the Lyon area (France) and
394 risk assessment for the downstream rivers. *Talanta* 70, 739-744.
- 395 [20] Postigo, C., Alda, M.J.L.D., Barcelo, D., (2008) Fully Automated determination in the low
396 nanogram per liter level of different classes of drugs and abuse in sewage water by On-line
397 solid-phase extraction-liquid-chromatography-electrospray-tandem mass spectrometry,
398 *Anal. Chem.*, 80, 3123-3134.
- 399 [21] Viglio, L., Aboulfadl, K., Mahvelat, A.D., Prevost, M., Sauve, S., (2008). On-line solid
400 phase extraction and liquid chromatography/tandem mass spectrometry to quantify
401 pharmaceuticals, pesticides and some metabolites in wastewaters, drinking, and surface
402 waters, *J. Environ. Monit.* 10, 482-489.

- 403 [22] Alnouti, Y., Srinivasan, K., Wadell, D., Bi, H., Kavetshaia, O., Gusev, A.I., (2005).
404 Development and application of a new on-line SPE system combined with LC-MS/MS
405 detection for high throughput direct analysis of pharmaceutical compounds in plasma,
406 *Journal of Chromatography A*. 1080, 99-106.
- 407 [23] Wang, S., Huang, W., Fang, G., He, J., Zhang, Y., (2008). On-line coupling of solid-phase
408 extraction to high-performance liquid chromatography for determination of estrogens in
409 environment, *Anal. Chim. Acta* 606, 194-201.
- 410 [24] Feitosa-Felizzola, J., Temime, B., Chiron, S., (2007). Evaluating on-line solid-phase
411 extraction coupled to liquid chromatography ion trap mass spectrometry for reliable
412 quantification and confirmation of several classes of antibiotics in urban wastewaters,
413 *Journal of Chromatography. A*. 1164, 95-104.
- 414 [25] Van De Steene, J., Lambert, W., Comparison of matrix effects in HPLC-MS/MS and UPLC-
415 MS/MS analysis of nine basic pharmaceuticals in surface waters. *Journal of The American*
416 *Society for Mass Spectrometry* 2008, 19 (5), 713.
- 417 [26] Swartz, M., Murphy, B. (2007). L'Ultra Performance LC: l'avenir de la chromatographie
418 liquid. *Les Technologie de laboratoire*, n°3 Mars-Avril, 20-22
- 419 [27] Cimetiere, N., Soutrel, I., Lemasle, M., Laplanche, A., Crocq, A. (2013) *Environmental*
420 *Technology*, 34(22), 3031-3041
- 421 [28] Kasprzyk-Hordern, B., Dinsdale, R.M., Guwy, A.J., (2008). The effect of signal
422 suppression and mobile phase composition on the simultaneous analysis of multiple classes
423 of acidic/neutral pharmaceuticals and personal care products in surface water by solid-phase
424 extraction and ultra-performance liquid chromatography–negative electrospray tandem
425 mass spectrometry. *Talanta*, 74, 1299–1312

426 [29] Balakrishnan, V.K., Terry, K.A, Toito, J., (2006). Determination of sulfonamide antibiotics
427 in wastewater: A comparison of solid phase microextraction and solid phase extraction
428 methods. *Journal of Chromatography A*, 113, 1–10.